Difference in Efficacy of Proton Pump Inhibitor Between New-onset and Recurrent Gastroesophageal Reflux Disease: Result from a Study of On-demand Versus Continuous Maintenance Therapy in Japan

Overview

Journal Hippokratia

Specialty General Medicine

Date 2015 Oct 6

PMID 26435648

Citations 2

Authors

A Nagahara

D Asaoka

M Hojo

H Sasaki

Y Shimada

K Matsumoto

H Ueyama

T Shibuya

N Sakamoto

T Osada

S Watanabe

Affiliations

Soon will be listed here.

Abstract

Background-objective: No study has focused on the difference in efficacy of maintenance therapy between patients with new-onset and recurrent gastroesophageal reflux disease (GERD). The aim of this study is to reveal this point.

Methods: Endoscopically proven GERD patients who had completed 8-week initial therapy were sequentially randomized to continuous arm (Omeprazole 20mg od) or on-demand arm (Omeprazole 20mg on-demand). Patients filled in daily symptoms and tablet usages for 24 weeks. Patients underwent upper GI endoscopy at 24 weeks. Symptom relief was defined as no symptoms for>6 days during a week. The numbers of patients who achieved symptom relief and mucosal healing were compared between the new-onset and recurrent groups in the continuous arm and in the on-demand arm, respectively.

Results: Among new-onset GERD [n=82 (continuous: 42 patients, on-demand: 40)], continuous arm achieved significant symptom-relief than in on-demand arm at 4*,5*,6** and 17*week. Among recurrent GERD [n=36(continuous: 17 patients, on-demand: 19)], continuous arm achieved significant symptom-relief at 1**,2*,3*,4*,5**,7**,8**,17* and 18* week, respectively (*<0.05,**<0.01). The number of healed patients was significantly higher in new-onset group (60/68, 88.2%) than in recurrent group (17/30, 56.7%) (<0.01).

Conclusion: Since therapeutic response during maintenance therapy was poor in recurrent GERD, continuous therapy is recommended in order to maintain symptom-relief and mucosal healing. Hippokratia 2015, 19 (1): 53-56.

Citing Articles

Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review.

Rossi A, Perrella L, Scotti S, Olmastroni E, Galimberti F, Ardoino I J Clin Med. 2024; 13(20).

PMID: 39458232 PMC: 11508458. DOI: 10.3390/jcm13206283.

Is It Time for Noncontinuous Therapy for Gastroesophageal Reflux Disease?.

DSouza S, Udemba S, Fass R Gastroenterol Hepatol (N Y). 2024; 20(5):273-280.

PMID: 39193078 PMC: 11345990.

References

Lee E, Kim N, Lee S, Park Y, Kim J, Jeong S . Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 30(2):154-64. DOI: 10.1111/j.1365-2036.2009.04021.x. View

Tsai H, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D . Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther. 2004; 20(6):657-65. DOI: 10.1111/j.1365-2036.2004.02155.x. View

Venables T, Newland R, Patel A, Hole J, Copeman M, Turbitt M . Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol. 1997; 32(7):627-32. DOI: 10.3109/00365529708996509. View

Carlsson R, Galmiche J, Dent J, Lundell L, Frison L . Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997; 11(3):473-82. DOI: 10.1046/j.1365-2036.1997.00167.x. View

Fujimoto K, Hongo M . Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol. 2010; 45(12):1193-200. DOI: 10.1007/s00535-010-0276-7. View

Thomson A, Sauve M, Kassam N, Kamitakahara H . Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010; 16(19):2323-30. PMC: 2874135. DOI: 10.3748/wjg.v16.i19.2323. View

Emerenziani S, Rescio M, Guarino M, Cicala M . Gastro-esophageal reflux disease and obesity, where is the link?. World J Gastroenterol. 2013; 19(39):6536-9. PMC: 3801365. DOI: 10.3748/wjg.v19.i39.6536. View

Hongo M . Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006; 41(2):95-9. DOI: 10.1007/s00535-006-1775-4. View

Jaspersen D, DIEHL K, SCHOEPPNER H, Geyer P, Martens E . A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther. 1998; 12(1):49-52. DOI: 10.1046/j.1365-2036.1998.00278.x. View

10.

Reimer C, Sondergaard B, Hilsted L, Bytzer P . Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009; 137(1):80-7, 87.e1. DOI: 10.1053/j.gastro.2009.03.058. View

11.

Vakil N, Shaker R, Johnson D, Kovacs T, BAERG R, Hwang C . The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001; 15(7):927-35. DOI: 10.1046/j.1365-2036.2001.01024.x. View

12.

Cicala M, Emerenziani S, Guarino M, Ribolsi M . Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013; 19(39):6529-35. PMC: 3801364. DOI: 10.3748/wjg.v19.i39.6529. View

13.

Armstrong D . Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008; 28(7):841-53. DOI: 10.1111/j.1365-2036.2008.03804.x. View

14.

Laursen L, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E . Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol. 1995; 30(9):839-46. DOI: 10.3109/00365529509101589. View

15.

Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M . Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013; 8(7):e69891. PMC: 3724738. DOI: 10.1371/journal.pone.0069891. View

16.

Nagahara A, Hojo M, Asaoka D, Sasaki H, Watanabe S . A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scand J Gastroenterol. 2014; 49(4):409-17. PMC: 4002634. DOI: 10.3109/00365521.2013.878380. View

17.

Lee S, Lien H, Chang C, Peng Y, Ko C, Chou M . Impact of body mass index and gender on quality of life in patients with gastroesophageal reflux disease. World J Gastroenterol. 2012; 18(36):5090-5. PMC: 3460337. DOI: 10.3748/wjg.v18.i36.5090. View

18.

Nagahara A, Hojo M, Asaoka D, Watanabe S . Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol. 2015; 3(2):61-8. DOI: 10.1007/s12328-010-0139-z. View

19.

Plein K, Hotz J, Wurzer H, Fumagalli I, Luhmann R, Schneider A . Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000; 12(4):425-32. DOI: 10.1097/00042737-200012040-00010. View

20.

Bardhan K, Muller-Lissner S, Bigard M, Bianchi Porro G, Ponce J, Hosie J . Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999; 318(7182):502-7. PMC: 27748. DOI: 10.1136/bmj.318.7182.502. View